This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genscript USA Inc, Piscataway, NJ 08854 for recombinant protein and plasmid expression for current Influenza A vaccine research.
The Laboratory of Viral Diseases (LVD) studies the basic mechanisms of viral entry into cells, regulation of viral gene expression, viral DNA replication, assembly and transport of viral proteins and particles, viral virulence, and humoral and cellular immunity.
These efforts requires the synthesis and purification of DNA plasmid reagents and for the development and testing of therapeutic antibody and vaccine candidates. The services being purchased will provide the materials needed for the quarterly Federal Drug Administration’s (FDA) testing results. Which are required to comply with the current vaccine trail approval.
No Substitutions are allowed on this project.
The Place of performance is 9000 Rockville Pike, Bethesda, MD 20892.
The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements.
THIS IS NOT A REQUEST FOR QUOTES.
All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2029689) to Ms. Skye duffner at [email protected] by 10:00 pm eastern standard time, August 17, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.